• There are no suggestions because the search field is empty.

MDR impact on MDSW: what has changed from MDD?

Author Avatar
Anne-Sophie Grell, RA Manager MD at QbD Group
Regulatory Affairs
Medical Devices
The introduction of MDR impacts CE-marked medical software (MDSW). Curious about the scope of this impact on your software? Read more below.
MDR impact on MDSW: what has changed from MDD? | QbD Group
7:26

Are you aware that the introduction of MDR may have affected your CE-marked medical software (MDSW)? Or will affect the CE marking of your first or next medical device software?

MDR – Regulation (EU) 2017/745 on medical devices – states in much more detail how software should be considered within the medical device environment (compared to the older MDD).

To give you an idea through a simple comparison, the word “software” appears 7 times in the MDD and 54 times in the MDR…

What does that mean? Well, this simple word count already indicates there’s more information on software in MDR, mostly regarding requirements.

In other words: the CE marking pathway for medical device software (MDSW) basically became stricter with MDR than with MDD. There are more specific requirements to meet.

In this blog post, you’ll learn how MDR impacts MDSW and what has changed from MDD.

 
 

How does MDR impact MDSW compared to MDD?

Software considered as Active devices in both MDR and MDD

Broadly speaking, the requirements in both documents are the same, but the MDR goes into more detail about the requirements, while the MDD was quite vague about them.

Both MDD and MDR consider Software to be “Active devices”

 

More classification rules in MDR

If you have already analyzed MDR a little, you know that there are many more classification rules than in MDD and they are more detailed, so it will facilitate the risk class evaluation.

 

Similar implementation rules in MDR and MDD

With regards to the classification rules’ implementation for software: they are the same in MDD and in MDR, even if the wording is a bit different.

  • MDD: Standalone software is considered an active medical device (Rules 9-11). Software, which drives a device or influences the use of a device, falls automatically in the same class.

  • MDR: Software, which drives a device or influences the use of a device, shall fall within the same class as the device. If the software is independent of any other device, it shall be classified in its own right (Rule 11).

Higher classification (and more constraints) under MDR

As is the case with the MDs, the MDR classification for SW is now generally higher than under MDD. This means that there are more requirements to meet compliance, especially regarding clinical data and Verification & Validation (see the section on Essential requirements).

 

For devices which incorporate software or which are medical software in themselves, the software must be validated according to the state of the art taking into account the principles of the development lifecycle, risk management, validation, and verification.

 

Which leaves a lot of room for interpretation… Different interpretations, in turn, may lead to discussions between Notified Bodies and manufacturers.

 

Notion of State of the Art reused in MDR

The notion of ‘State of the Art’ means that you must apply the latest regulations and the most recent IEC standards for SW development, risk analysis, etc.

This notion is also reused in the MDR with additional information about reducing risk, performance, mobile application, network security, and IFU:

14.2 Devices shall be designed and manufactured in such a way as to remove or reduce as far as possible: (d) the risks associated with the possible negative interaction between software and the IT environment within which it operates and interacts

17. Electronic programmable systems — devices that incorporate electronic programmable systems and software that are devices in themselves

17.1. Devices that incorporate electronic programmable systems, including software, or software that are devices in themselves, shall be designed to ensure repeatability, reliability and performance in line with their intended use. In the event of a single fault condition, appropriate means shall be adopted to eliminate or reduce as far as possible consequent risks or impairment of performance.

17.2. For devices that incorporate software or for software that are devices in themselves, the software shall be developed and manufactured in accordance with the state of the art taking into account the principles of development life cycle, risk management, including information security, verification and validation. 5.5.2017 L 117/100 Official Journal of the European Union EN

17.3. Software referred to in this Section that is intended to be used in combination with mobile computing platforms shall be designed and manufactured taking into account the specific features of the mobile platform (e.g. size and contrast ratio of the screen) and the external factors related to their use (varying environment as regards level of light or noise).

17.4. Manufacturers shall set out minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorized access, necessary to run the software as intended.

(23.4 f) where applicable, information allowing the healthcare professional to verify if the device is suitable and select the corresponding software and accessories;

(23.4(ab)) for devices that incorporate electronic programmable systems, including software, or software that are devices in themselves, minimum requirements concerning hardware, IT networks characteristics and IT security measures, including protection against unauthorized access, necessary to run the software as intended.

As a result, manufacturers must update their technical documentation because there are more requirements to comply with the regulation.

 

Additional requirements to be included in the technical documentation for MDR

There are also some additional descriptions on the technical documentation including pre-clinical &clinical data and UDI implementation (Annex II), Clinical Evaluation & PMCF requirements (Annex XIV), and Clinical investigation (Annex XV) for MDSW.

In addition, there are some hints on how Notified Bodies need to review the technical file for SW (Annex VII).

As more requirements are placed on the technical documentation under the MDR, it is nice to have an idea of how that documentation will be assessed by the Notified Body.

And, for the first time, the regulation clearly provides some information on HOW the notified body should assess the documentation.

 

Conclusion: more stringent CE marking pathway in MDR

 

The CE marking pathway for MDSW has become more stringent with MDR than with MDD. There are more and more specific requirements to meet and classification by default leans towards a higher risk classification

As a result, medical device manufacturers first need to check their risk classification and then review their technical documentation accordingly, especially the clinical evidence.

Need help reclassifying your software or updating your technical documentation? Our RA and PMO teams can:

  • support you to identify the gap analysis between MDD and MDR for your Software.
  • help you to get new CE marking
 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Case study

A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader​

QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA languages while meeting stringent regulatory deadlines.
preview_image
Whitepaper

Medical Device Regulation (MDR) Checklist

Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR compliance.
preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Whitepaper

Mobile health on the rise: exploring the regulatory landscape for reimbursement

This whitepaper will help you navigate the maze of the DTx regulatory environment, highlighting several important countries and regulations.
preview_image
Whitepaper

Clinical investigations under MDR: key insights and practical experiences

This whitepaper covers clinical investigation authorization under MDR, the EU Legal Representative's role, and the MDR's impact on study conduct and post-market surveillance.
preview_image
Case study

CE Mark Renewal for bioXtra Products: A Success Story

Discover how Lifestream Pharma successfully renewed the CE mark for their BioXtra Dry Mouth products under the EU MDR. Learn about the challenges faced, the approach taken for compliance, and the results achieved.
preview_image
Webinar

Technical Documentation Essentials for Medical Device Software

Gain practical insights on crafting MDR-compliant technical documentation for Medical Device Software.
preview_image
Webinar

Getting Started: Overcoming Initial Obstacles in Medical Device Software Development

Watch our webinar on demand and learn about regulatory obstacles, MDR, AI Act, and best practices for medical device software development and market entry.
preview_image
Webinar

Mastering Clinical Performance Studies under IVDR

In the evolving regulatory landscape of IVDs, demonstrating clinical performance is more crucial and challenging than ever. Discover more in this webinar on demand.
preview_image
Whitepaper

Clinical evidence for In Vitro Diagnostics under IVDR

In this whitepaper, we will guide you through the documents required for the demonstration of clinical evidence under the IVDR. Download now.
preview_image
Webinar

Post-Market Surveillance Requirements for Medical Devices and IVDs

Learn about post-market surveillance requirements under MDR and IVDR regulations. Gain insights from industry experts in this on-demand webinar.
preview_image
Whitepaper

The key role of Regulatory Affairs in the pharmaceutical industry: from drug development to commercialization

Discover the key role of Regulatory Affairs in pharma and how Regulatory Affairs teams support product lifecycle management in this whitepaper. Download now.
preview_image
Webinar

3D Printing in the Healthcare World

Explore the challenges and opportunities of 3D printing in healthcare, featuring expert insights on regulations, pitfalls, and efficiency.
preview_image
Webinar

IVDR Extension Explained: Tips & Strategies

Gain valuable insights on the IVDR extension and its impact on IVD manufacturers with our webinar on demand.
preview_image
Whitepaper

Innovations in ATMP: state of the industry in 2024

This whitepaper explores the innovations in ATMP and solutions in detail, with a focus on the current landscape as of April 2024. Download now.
preview_image
Case study

The journey toward IVDR compliance for the LVOne device

QbD Group helped Upfront Diagnostics gain entry into the MD/IVD industry by supporting them on their path to ISO 13485 certification.
preview_image
Case study

Ensuring a smooth MDR transition for Oystershell's medical devices

The landscape of medical device regulations is constantly evolving, making it a challenge for companies to keep up. Our collaboration with Oystershell, which began in July 2023, highlights our expertise in transforming complex challenges into success stories, all with a touch of QbD Clinical magic.
preview_image
Case study

Successful clinical evaluation supports rapid CE marking of Minze Health's Uroflowmeter

QbD Clinical assisted Minze Health, a urology-focused medical devices company, in obtaining CE marking under MDR through clinical evaluation.
preview_image
Webinar

The Medical Device CE Certification Pathway Explained: From Classification to Conformity Assessment by the Notified Body

Learn about the Medical Device CE Certification Pathway, from classification to conformity assessment by a Notified Body. Join our webinar on demand.
preview_image
Case study

Helping Relu to comply with changing regulations

QbD Group supported software company Relu with their expertise to comply with changing regulations.
preview_image
Case study

Quickly bringing a new COVID-19 medical device to market

Obtaining the required government certifications for a medical device is always a challenge. Especially when the COVID clock is ticking.